Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells

British Journal of Cancer

Volumn 82, Issue 4, 2000, Pages 905-912

  Di Paolo, A ^a   Danesi, R ^a   Nardini, D ^a   Bocci, G ^a   Innocenti, F ^a   Fogli, S ^a   Barachini, S ^a   Marchetti, A ^a   Bevilacqua, G ^a   Del Tacca, M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Apoptosis; Colorectal neoplasms; Manumycin; Protein isoprenylation; ras proteins

Indexed keywords

MANUMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21; RAS PROTEIN;

APOPTOSIS; ARTICLE; CELL LYSATE; CELL MEMBRANE; COLON TUMOR; CONTROLLED STUDY; CYTOPLASM; DNA CLEAVAGE; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; ISOPRENYLATION; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

EID: 0033953838     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1018     Document Type: Article

References (31)

1. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689
2. Corsini A, Maggi FM and Catapano AL (1995) Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 31: 9-27
3. Cox AD and Der CJ (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1333: F51-F71
4. 5) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 47: 1106-1111
5. Danesi R, Nardini D, Basolo F, Del Tacca M, Samid D and Myers CE (1996) Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol 49: 972-979
6. Giancotti FG and Mainiero F (1994) Integrin-mediated adhesion and signaling in tumorigenesis. Biochim Biophys Acta 1198: 47-64
7. Giannakouros T and Magee AI (1993) Protein prenylation and associated modifications. In: Lipid Modifications of Proteins, Schlesinger MJ (ed), pp. 136-162. CRC Press; Boca Raton, FL
8. Gibbs JB and Oliff A (1997) The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37: 143-146
9. Gibbs JB, Oliff A and Kohl NE (1994) Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutics. Cell 77: 175-178
10. Hara M and Han M (1995) Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc Natl Acad Sci USA 92: 3333-3337
11. Hara M, Kazuhito A, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M and Tamanoi F (1993) Identification of ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 90: 2281-2285
12. Ikeda M, Koyama S, Okazaki M, Dohi K and Kikuchi A (1995) Rap1 p21 regulates the interaction of ras p21 with RGL, a new effector protein of ras p21. FEBS Lett 375: 37-40
13. Kawabata H, Anzai N, Yoshida Y and Okuma M (1994) A new method for quantitative estimation of the degree of DNA fragmentation utilizing agarose gel electrophoresis. Int J Hematol 59: 311-316
14. Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A, Conti CJ and Jorcano JL (1996) Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56: 5391-5396
15. Levitzky A (1996) Targeting signal transduction for disease therapy. Curr Opin Cell Biol 8: 239-244
16. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with folin phenol reagent. J Biol Chem 193: 265-267
17. Lowy DR and Willumsen BM (1993) Function and regulation of ras. Annu Rev Biochem 62: 851-891
18. Maltese WA (1990) Post-translational modification of proteins by isoprenoids in mammalian cells. FASEB J 4: 3319-3328
19. Marchetti A, Buttitta F, Pellegrini S, Chella A, Bertacca G, Filardo A, Tognoni V, Ferreli F, Signorini E, Angeletti CA and Bevilacqua G (1996) Bronchioloalveolar lung carcinomas: K-ras mutations constant events in the mucinous subtype. J Pathol 179: 254-259
20. Marshall CJ (1993) Protein prenylation: a mediator of protein -protein interactions. Science 259: 1865-1866
21. Marshall CJ (1996) Ras effectors. Curr Opin Cell Biol 8: 197-204
22. Marshall MS (1995) Ras target proteins in eukaryotic cells. FASEB J 9: 1311-1318
23. Nagase T, Kawata S, Tamura S, Matsuda Y, Inui Y, Yamasaky E, Ishiguro H, Ito T and Matsuzawa Y (1996) Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation. Int J Cancer 65: 620-626
24. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD and Garcia AM (1995) Inhibition of human tumor xenograft growth by treatment with farnesyl transferase inhibitor B956. Cancer Res 55: 5310-5314
25. Nassar N, Horn G, Hermann C, Scherer A, McCormick F and Wittinghofer A (1995) The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature 375: 554-560
26. Perez-Sala D and Mollinedo F (1994) Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199: 1209-1215
27. Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A and Halpern J-P (1995) Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 58: 625-628
28. Rodenhuis S, Boerrigter L, Top B, Slebos RJC, Mooi WJ, van't Veer L and van Zandwijk N (1997) Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 15: 285-291
29. Tamanoi F (1993) Inhibitors of Ras farnesyltransferases. Trends Biol Sci 18: 349-353
30. Veerkamp JH, Smith JWA, Benders AAGM and Oosterhof A (1996) Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Biochim Biophys Acta 1315: 217-223
31. Wittinghofer A and Herrman C (1995) Ras-effector interactions, the problem of specificity. FEBS Lett 369: 52-56